Lung CancerLUNG-ISNCT07716280
Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics
A study testing Text Messages (TM+), Chat bot (CA) and Video in people with Lung Cancer, run by University of Utah at 1 site in United States.
Trial summary
The long-term goal of this program of research is to increase the reach of Lung Cancer Screening (LCS) among low-resource healthcare settings and populations. The proposed project, LUNG-IS, is a mixed-methods, pre-post quasi-experimental design conducted in three Utah safety-net healthcare system clinics. Read more about this study
- Who is it for?
- Ages 50 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Text Messages (TM+), Chat bot (CA) and Video
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 800 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2026to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Current or former, male and female, smokers.
- Age 50-80.
- Primary language English or Spanish.
- Have a phone that can send/receive text messages.
Who cannot join
- Patients who have never smoked.
- Patients who are under the age of 50 or above the age of 80.
- Primary language other than English or Spanish.
- Do not have access to a phone that can send/receive text messages.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Huntsman Cancer Institute/ University of Utah
Salt Lake City, Utah, 84112
Indy Li, MS, 801-213-5697, indy.li@hci.utah.edu
Chelsey Schlechter, MPH, PhD
About this study
Official title: Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics (LUNG-IS) - PATIENT
The long-term goal of this program of research is to increase the reach of Lung Cancer Screening (LCS) among low-resource healthcare settings and populations. The proposed project, LUNG-IS, is a mixed-methods, pre-post quasi-experimental design conducted in three Utah safety-net healthcare system clinics.
LUNG-IS employs a comprehensive conceptual model with theories, models, and frameworks of implementation and behavioral science, uses rigorous mixed-methods to evaluate factors that influence implementation of LCS, and uses patient navigation to facilitate clinic-community linkages.
LUNG-IS leverages existing pathways to care and Centralized Hub infrastructure that enables eligibility assessment, LCS Shared Decision Making (SDM) with clinical decision support, screening referral, and screening logistics assistance to help overcome barriers to LCS completion. The Centralized Hub model uses ubiquitous technologies (i.e., text messaging/telehealth) to enable patients to be assessed for LCS eligibility, engage in SDM if eligible, and be referred for LCS. For patients who decide to complete LCS, they will be provided patient navigation via Community Health Workers designed to address logistical barriers, hesitancy, and financial constraints around completing LCS.
- Conditions
- Lung Cancer
- Being tested
- Text Messages (TM+), Chat bot (CA), Video, Reactive Patient Navigation (RPN), Proactive Patient Navigation (PPN)
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Text Messages (TM+)Behavioural
Basic text messages sent directly to the patient's cell phone.
Chat bot (CA)Behavioural
Chat bot to answer frequently asked LCS questions.
VideoBehavioural
Educational video about LCS.
Reactive Patient Navigation (RPN)Behavioural
Reactive patient navigation to help get to the LCS appointment.
Proactive Patient Navigation (PPN)Behavioural
Proactive patient navigation to help get to the LCS appointment.
| Study group | Role | What they receive |
|---|---|---|
| Stage 1: TM+ | Other | Basic text messages sent directly to the patient's cell phone. Receives: Behavioral: Text Messages (TM+) |
| Stage 1: TM+, CA | Other | Basic text messages sent directly to the patient's cell phone. Also includes the option for chat bot to answer frequently asked LCS questions. Receives: Behavioral: Text Messages (TM+); Behavioral: Chat bot (CA) |
| Stage 1: TM+, Video | Other | Basic text messages sent directly to the patient's cell phone. Also includes the option for an educational video about LCS. Receives: Behavioral: Text Messages (TM+); Behavioral: Video |
| Stage 1: TM+, CA, Video | Other | Basic text messages sent directly to the patient's cell phone. Also includes the option for chat bot to answer frequently asked LCS questions and option for educational video about LCS.
Patients who complete SDM and are referred to LCS will also be assigned to one of the following conditions. Descriptions of these conditions are as follows: Receives: Behavioral: Text Messages (TM+); Behavioral: Chat bot (CA); Behavioral: Video |
| Stage 2: TM+, RPN | Other | Patients who complete SDM and are referred to LCS may be assigned to this condition
Patients will receive basic text messages and reactive patient navigation to help get to the LCS appointment. Receives: Behavioral: Text Messages (TM+); Behavioral: Reactive Patient Navigation (RPN) |
| Stage 2:TM+, PPN | Other | Patients who complete SDM and are referred to LCS may be assigned to this condition
Patients will receive basic text messages and proactive patient navigation to help get to the LCS appointment.
Patients who need transportation financial assistance will receive transportation vouchers to help get them to and from their LCS appointment. Receives: Behavioral: Text Messages (TM+); Behavioral: Proactive Patient Navigation (PPN) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Impact of Implementation Strategies on Lung Cancer Screening (LCS) eligibility screening
Evaluate the impact of implementation strategies on Lung Cancer Screening (LCS) eligibility screening. This outcome measure will report the proportion of participants who complete LCS eligibility screening.
Measured: up to 15 weeks after study enrollment
Secondary outcomes (2)
Impact of Implementation Strategies on LCS Shared Decision Making (SDM) completion
Evaluate the impact of implementation strategies on Shared Decision Making (SDM) completion. This outcome measure will report the proportion of patients who complete SDM.
Measured: up to 7 weeks after completion of LCS eligibility screen
Impact of Implementation Strategies on LCS Completion
Evaluate the impact of implementation strategies on LCS completion. This outcome measure will report the proportion of participants who complete LCS.
Measured: up to 6 months after placement of LCS referral
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jul 2026
- Study start1 Jan 2026
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by University of UtahThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Collaborators
- Centers for Disease Control and Prevention
- Responsible party
- Sponsor
- Investigators
- Chelsey Schlechter, MPH, PhD, Principal investigator, Huntsman Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07716280
- Sponsor's protocol ID
- 187448
- Other IDs
- 1U48DP006855-01
- Acronym
- LUNG-IS
- Status last verified
- Jul 2026
- First submitted
- 2 Jul 2026
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics (LUNG-IS) - PATIENT
- ClinicalTrials.gov ID
- NCT07716280
- Acronym / sponsor ID
- LUNG-IS / 187448
- Conditions
- Lung Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Collaborators
- Centers for Disease Control and Prevention
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 21 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The long-term goal of this program of research is to increase the reach of Lung Cancer Screening (LCS) among low-resource healthcare settings and populations. The proposed project, LUNG-IS, is a mixed-methods, pre-post quasi-experimental design conducted in three Utah safety-net healthcare system clinics.
LUNG-IS employs a comprehensive conceptual model with theories, models, and frameworks of implementation and behavioral science, uses rigorous mixed-methods to evaluate factors that influence implementation of LCS, and uses patient navigation to facilitate clinic-community linkages.
LUNG-IS leverages existing pathways to care and Centralized Hub infrastructure that enables eligibility assessment, LCS Shared Decision Making (SDM) with clinical decision support, screening referral, and screening logistics assistance to help overcome barriers to LCS completion. The Centralized Hub model uses ubiquitous technologies (i.e., text messaging/telehealth) to enable patients to be assessed for LCS eligibility, engage in SDM if eligible, and be referred for LCS. For patients who decide to complete LCS, they will be provided patient navigation via Community Health Workers designed to address logistical barriers, hesitancy, and financial constraints around completing LCS.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Stage 1: TM+ | Other | Behavioral: Text Messages (TM+)Basic text messages sent directly to the patient's cell phone. |
| Stage 1: TM+, CA | Other | Behavioral: Text Messages (TM+), Behavioral: Chat bot (CA)Basic text messages sent directly to the patient's cell phone. Also includes the option for chat bot to answer frequently asked LCS questions. |
| Stage 1: TM+, Video | Other | Behavioral: Text Messages (TM+), Behavioral: VideoBasic text messages sent directly to the patient's cell phone. Also includes the option for an educational video about LCS. |
| Stage 1: TM+, CA, Video | Other | Behavioral: Text Messages (TM+), Behavioral: Chat bot (CA), Behavioral: VideoBasic text messages sent directly to the patient's cell phone. Also includes the option for chat bot to answer frequently asked LCS questions and option for educational video about LCS. Patients who complete SDM and are referred to LCS will also be assigned to one of the following conditions. Descriptions of these conditions are as follows: |
| Stage 2: TM+, RPN | Other | Behavioral: Text Messages (TM+), Behavioral: Reactive Patient Navigation (RPN)Patients who complete SDM and are referred to LCS may be assigned to this condition Patients will receive basic text messages and reactive patient navigation to help get to the LCS appointment. |
| Stage 2:TM+, PPN | Other | Behavioral: Text Messages (TM+), Behavioral: Proactive Patient Navigation (PPN)Patients who complete SDM and are referred to LCS may be assigned to this condition Patients will receive basic text messages and proactive patient navigation to help get to the LCS appointment. Patients who need transportation financial assistance will receive transportation vouchers to help get them to and from their LCS appointment. |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Current or former, male and female, smokers.
- Age 50-80.
- Primary language English or Spanish.
- Have a phone that can send/receive text messages.
Key exclusion criteria (4 listed)
- Patients who have never smoked.
- Patients who are under the age of 50 or above the age of 80.
- Primary language other than English or Spanish.
- Do not have access to a phone that can send/receive text messages.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Text Messages (TM+)Basic text messages sent directly to the patient's cell phone. | Behavioural | Stage 1: TM+, Stage 1: TM+, CA, Stage 1: TM+, CA, Video, Stage 1: TM+, Video, Stage 2: TM+, RPN, Stage 2:TM+, PPN |
| Chat bot (CA)Chat bot to answer frequently asked LCS questions. | Behavioural | Stage 1: TM+, CA, Stage 1: TM+, CA, Video |
| VideoEducational video about LCS. | Behavioural | Stage 1: TM+, CA, Video, Stage 1: TM+, Video |
| Reactive Patient Navigation (RPN)Reactive patient navigation to help get to the LCS appointment. | Behavioural | Stage 2: TM+, RPN |
| Proactive Patient Navigation (PPN)Proactive patient navigation to help get to the LCS appointment. | Behavioural | Stage 2:TM+, PPN |
Primary outcome
Impact of Implementation Strategies on Lung Cancer Screening (LCS) eligibility screening
Time frame: up to 15 weeks after study enrollment
Evaluate the impact of implementation strategies on Lung Cancer Screening (LCS) eligibility screening. This outcome measure will report the proportion of participants who complete LCS eligibility screening.
2 secondary outcomes
Impact of Implementation Strategies on LCS Shared Decision Making (SDM) completion
Time frame: up to 7 weeks after completion of LCS eligibility screen
Impact of Implementation Strategies on LCS Completion
Time frame: up to 6 months after placement of LCS referral
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chelsey Schlechter, MPH, PhD principal investigator
Huntsman Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Text Messages (TM+), Chat bot (CA) and Video in people with Lung Cancer, run by University of Utah at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Indy Li, MS (801-213-5697, indy.li@hci.utah.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Impact of Implementation Strategies on Lung Cancer Screening (LCS) eligibility screening (time frame: up to 15 weeks after study enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.